European Archives - Page 350 of 1053 - European Medical Journal

Kite Pharma’s Christi Shaw on the story behind her drive

Christi Shaw, former CEO, Kite Pharma, shares her thoughts on improving access to cell therapies and her motivations for working in oncology

Pharma in the US

Exploring the current state of the US pharmaceutical market, this article investigates the balance between innovation and access to care in the country.

It Takes Guts to Treat Gastrointestinal Disorders

Alex Ford joins Jonathan on this episode of the EMJ Podcast to discuss disorders of gut–brain interaction and gastrointestinal disorders

My journey with diversity, equity and inclusion

Roche’s Davidek Herron offers his thoughts on the state of diversity, equity and inclusion in the pharma industry.

Addressing the Impacts of Sex and Gender on Respiratory Care

Chronic lung disease currently accounts for a large percentage of deaths in both males and females. This podcast challenges stereotypes and provides insights into the differences in respiratory care between sexes.

Mapping a path to personalised medicine

Despite continued advances in personalised medicine, there is still more to be done to encourage policy makers and payers to back these life-changing initiatives.

Valproate-Induced Pancreatitis in a Patient with Bipolar Disorder

Sodium valproate, or valproic acid (VPA), is an antiepileptic drug used for the treatment of epilepsy, bipolar disorder, migraine headache, and diabetic-neuropathy related pain. Valproate-induced pancreatitis is an idiosyncratic reaction of the drug, commonly seen in paediatrics…

Pharma in the UK

In 2021, the UK was named the sixth biggest pharmaceutical market, but it’s facing challenges to further growth. Read to find out more.

Dr Zsuzsanna Devecseri

Access to oncology treatments, diversity and lessons in leadership

The GOLD team are joined by Dr Zsuzsanna Devecseri, Vice President and Head of Global Oncology Medical, Sanofi Genzyme, to discuss her career journey and varied experience within the pharmaceutical industry.

Widal Positivity: Tuberculosis Diagnosis and Fluoroquinolone Resistance

Drug resistance among patients with tuberculosis (TB) is an emergent topic that requires intervention. According to a survey of TB drug resistance in India, resistance to any fluoroquinolones (FQ) reported in cases of multidrug resistance (MDR) to TB was 21.82%.